vs
百胜餐饮集团（AKA）与Ultragenyx Pharmaceutical Inc.（RARE）财务数据对比。点击上方公司名可切换其他公司
Ultragenyx Pharmaceutical Inc.的季度营收约是百胜餐饮集团的1.3倍（$207.3M vs $163.9M），百胜餐饮集团净利率更高（-8.8% vs -62.0%，领先53.2%），Ultragenyx Pharmaceutical Inc.同比增速更快（25.9% vs 3.1%），百胜餐饮集团自由现金流更多（$-3.0M vs $-100.8M），过去两年Ultragenyx Pharmaceutical Inc.的营收复合增速更高（38.0% vs 18.5%）
百胜餐饮集团是美国跨国快餐企业，1977年百事可乐收购肯德基、必胜客、塔可贝尔后将其整合为旗下子公司，1997年百事可乐剥离该业务后，这些品牌整合为独立的百胜集团。目前百胜集团运营肯德基、必胜客、塔可贝尔、哈比特汉堡等多个餐饮品牌，同时布局相关餐饮科技业务。
Ultragenyx Pharmaceutical Inc.是一家总部位于美国的生物制药企业，专注于研发罕见病和超罕见遗传病的创新治疗方案，这类疾病目前大多无获批疗法，存在大量未被满足的临床需求。公司覆盖生物制剂、小分子药物、基因疗法、反义寡核苷酸及mRNA等多种药物技术平台，研发管线涵盖骨骼、内分泌、代谢、肌肉及中枢神经系统疾病领域。
AKA vs RARE — 直观对比
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $163.9M | $207.3M |
| 净利润 | $-14.5M | $-128.6M |
| 毛利率 | 55.6% | — |
| 营业利润率 | -6.6% | -54.7% |
| 净利率 | -8.8% | -62.0% |
| 营收同比 | 3.1% | 25.9% |
| 净利润同比 | -55.0% | 3.5% |
| 每股收益（稀释后） | $-1.35 | $-1.28 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
| Q4 25 | $163.9M | $207.3M | ||
| Q3 25 | $147.1M | $159.9M | ||
| Q2 25 | $160.5M | $166.5M | ||
| Q1 25 | $128.7M | $139.3M | ||
| Q4 24 | $159.0M | $164.6M | ||
| Q3 24 | $149.9M | $139.5M | ||
| Q2 24 | $148.9M | $147.0M | ||
| Q1 24 | $116.8M | $108.8M |
| Q4 25 | $-14.5M | $-128.6M | ||
| Q3 25 | $-5.0M | $-180.4M | ||
| Q2 25 | $-3.6M | $-115.0M | ||
| Q1 25 | $-8.3M | $-151.1M | ||
| Q4 24 | $-9.4M | $-133.2M | ||
| Q3 24 | $-5.4M | $-133.5M | ||
| Q2 24 | $-2.3M | $-131.6M | ||
| Q1 24 | $-8.9M | $-170.7M |
| Q4 25 | 55.6% | — | ||
| Q3 25 | 59.1% | — | ||
| Q2 25 | 57.5% | — | ||
| Q1 25 | 57.2% | — | ||
| Q4 24 | 55.9% | — | ||
| Q3 24 | 58.0% | — | ||
| Q2 24 | 57.7% | — | ||
| Q1 24 | 56.2% | — |
| Q4 25 | -6.6% | -54.7% | ||
| Q3 25 | -1.0% | -106.9% | ||
| Q2 25 | -0.3% | -64.8% | ||
| Q1 25 | -4.2% | -102.6% | ||
| Q4 24 | -1.8% | -74.3% | ||
| Q3 24 | -1.4% | -94.6% | ||
| Q2 24 | 0.4% | -79.1% | ||
| Q1 24 | -5.2% | -151.9% |
| Q4 25 | -8.8% | -62.0% | ||
| Q3 25 | -3.4% | -112.8% | ||
| Q2 25 | -2.3% | -69.0% | ||
| Q1 25 | -6.5% | -108.5% | ||
| Q4 24 | -5.9% | -80.9% | ||
| Q3 24 | -3.6% | -95.7% | ||
| Q2 24 | -1.5% | -89.5% | ||
| Q1 24 | -7.6% | -156.8% |
| Q4 25 | $-1.35 | $-1.28 | ||
| Q3 25 | $-0.46 | $-1.81 | ||
| Q2 25 | $-0.34 | $-1.17 | ||
| Q1 25 | $-0.78 | $-1.57 | ||
| Q4 24 | $-0.88 | $-1.34 | ||
| Q3 24 | $-0.51 | $-1.40 | ||
| Q2 24 | $-0.22 | $-1.52 | ||
| Q1 24 | $-0.85 | $-2.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $20.3M | $421.0M |
| 总债务越低越好 | $111.1M | — |
| 股东权益账面价值 | $97.8M | $-80.0M |
| 总资产 | $397.4M | $1.5B |
| 负债/权益比越低杠杆越低 | 1.14× | — |
8季度趋势，按日历期对齐
| Q4 25 | $20.3M | $421.0M | ||
| Q3 25 | $23.4M | $202.5M | ||
| Q2 25 | $23.1M | $176.3M | ||
| Q1 25 | $26.7M | $127.1M | ||
| Q4 24 | $24.2M | $174.0M | ||
| Q3 24 | $23.1M | $150.6M | ||
| Q2 24 | $25.5M | $480.7M | ||
| Q1 24 | $21.9M | $112.3M |
| Q4 25 | $111.1M | — | ||
| Q3 25 | $111.3M | — | ||
| Q2 25 | $108.7M | — | ||
| Q1 25 | $119.9M | — | ||
| Q4 24 | $111.7M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $106.9M | — | ||
| Q1 24 | $103.6M | — |
| Q4 25 | $97.8M | $-80.0M | ||
| Q3 25 | $110.1M | $9.2M | ||
| Q2 25 | $114.1M | $151.3M | ||
| Q1 25 | $111.5M | $144.2M | ||
| Q4 24 | $117.6M | $255.0M | ||
| Q3 24 | $136.9M | $346.8M | ||
| Q2 24 | $136.6M | $432.4M | ||
| Q1 24 | $135.5M | $140.3M |
| Q4 25 | $397.4M | $1.5B | ||
| Q3 25 | $411.3M | $1.2B | ||
| Q2 25 | $410.8M | $1.3B | ||
| Q1 25 | $396.6M | $1.3B | ||
| Q4 24 | $385.2M | $1.5B | ||
| Q3 24 | $404.1M | $1.5B | ||
| Q2 24 | $388.8M | $1.6B | ||
| Q1 24 | $355.8M | $1.3B |
| Q4 25 | 1.14× | — | ||
| Q3 25 | 1.01× | — | ||
| Q2 25 | 0.95× | — | ||
| Q1 25 | 1.08× | — | ||
| Q4 24 | 0.95× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.76× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $1.7M | $-99.8M |
| 自由现金流经营现金流 - 资本支出 | $-3.0M | $-100.8M |
| 自由现金流率自由现金流/营收 | -1.9% | -48.6% |
| 资本支出强度资本支出/营收 | 2.9% | 0.5% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-633.0K | $-472.0M |
8季度趋势，按日历期对齐
| Q4 25 | $1.7M | $-99.8M | ||
| Q3 25 | $4.7M | $-91.4M | ||
| Q2 25 | $11.9M | $-108.3M | ||
| Q1 25 | $-1.9M | $-166.5M | ||
| Q4 24 | $7.0M | $-79.3M | ||
| Q3 24 | $-2.1M | $-67.0M | ||
| Q2 24 | $3.5M | $-77.0M | ||
| Q1 24 | $-7.7M | $-190.7M |
| Q4 25 | $-3.0M | $-100.8M | ||
| Q3 25 | $317.0K | $-92.7M | ||
| Q2 25 | $7.4M | $-110.7M | ||
| Q1 25 | $-5.3M | $-167.8M | ||
| Q4 24 | $3.1M | $-79.5M | ||
| Q3 24 | $-7.1M | $-68.6M | ||
| Q2 24 | $1.5M | $-79.0M | ||
| Q1 24 | $-8.4M | $-193.9M |
| Q4 25 | -1.9% | -48.6% | ||
| Q3 25 | 0.2% | -58.0% | ||
| Q2 25 | 4.6% | -66.5% | ||
| Q1 25 | -4.1% | -120.5% | ||
| Q4 24 | 2.0% | -48.3% | ||
| Q3 24 | -4.7% | -49.2% | ||
| Q2 24 | 1.0% | -53.7% | ||
| Q1 24 | -7.2% | -178.2% |
| Q4 25 | 2.9% | 0.5% | ||
| Q3 25 | 3.0% | 0.8% | ||
| Q2 25 | 2.8% | 1.5% | ||
| Q1 25 | 2.7% | 1.0% | ||
| Q4 24 | 2.5% | 0.1% | ||
| Q3 24 | 3.3% | 1.2% | ||
| Q2 24 | 1.3% | 1.4% | ||
| Q1 24 | 0.6% | 3.0% |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AKA
暂无分部数据
RARE
| Royalty | $105.6M | 51% |
| Products | $101.7M | 49% |
